The potential economic value of a ‘universal’ (multi‐year) influenza vaccine
Open Access
- 21 September 2011
- journal article
- research article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 6 (3), 167-175
- https://doi.org/10.1111/j.1750-2659.2011.00288.x
Abstract
Please cite this paper as: Lee et al. (2011) The potential economic value of a ‘universal’ (multi‐year) influenza vaccine. Influenza and Other Respiratory Viruses 6(3), 167–175. Background Limitations of the current annual influenza vaccine have led to ongoing efforts to develop a ‘universal’ influenza vaccine, i.e., one that targets a ubiquitous portion of the influenza virus so that the coverage of a single vaccination can persist for multiple years. Objectives To estimate the economic value of a ‘universal’ influenza vaccine compared to the standard annual influenza vaccine, starting vaccination in the pediatric population (2–18 year olds), over the course of their lifetime. Patient/Methods Monte Carlo decision analytic computer simulation model. Results Universal vaccine dominates (i.e., less costly and more effective) the annual vaccine when the universal vaccine cost ≤$100/dose and efficacy ≥75% for both the 5‐ and 10‐year duration. The universal vaccine is also dominant when efficacy is ≥50% and protects for 10 years. A $200 universal vaccine was only cost‐effective when ≥75% efficacious for a 5‐year duration when annual compliance was 25% and for a 10‐year duration for all annual compliance rates. A universal vaccine is not cost‐effective when it cost $200 and when its efficacy is ≤50%. The cost‐effectiveness of the universal vaccine increases with the duration of protection. Conclusions Although development of a universal vaccine requires surmounting scientific hurdles, our results delineate the circumstances under which such a vaccine would be a cost‐effective alternative to the annual influenza vaccine.Keywords
This publication has 36 references indexed in Scilit:
- Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infectionThe Journal of Experimental Medicine, 2011
- Potent CD8(+) T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1Clinical Infectious Diseases, 2010
- Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypesProceedings of the National Academy of Sciences of the United States of America, 2010
- A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemicVaccine, 2010
- Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstaclesVaccine, 2010
- The timing of influenza vaccination for older adults (65 years and older)Vaccine, 2009
- Attacking the flu: Neutralizing antibodies may lead to 'universal' vaccineNature Medicine, 2009
- Antibody Recognition of a Highly Conserved Influenza Virus EpitopeScience, 2009
- Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge StudiesAmerican Journal of Epidemiology, 2008
- Mapping the Antigenic and Genetic Evolution of Influenza VirusScience, 2004